Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy

Impact of anti-PD-1 and anti-CTLA-4 on the HIV reservoir in people living with HIV with cancer on antiretroviral therapy: The AIDS Malignancy Consortium-095 study

(2021) Thomas A Rasmussen et al.   CLINICAL INFECTIOUS DISEASES

Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency

(2021) Jennifer M. Zerbato et al.   EBioMedicine

Suspected Immune-Related Adverse Events with an Anti-PD-1 Inhibitor in Healthy People with HIV

(2021) Cynthia L. GAY et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021

(2021) Steven G. Deeks et al.   NATURE MEDICINE

Combination Immune Checkpoint Blockade to Reverse HIV Latency

(2020) Renée M. Van der Sluis et al.   JOURNAL OF IMMUNOLOGY

Robust Expansion of HIV CAR T Cells Following Antigen Boosting in ART-Suppressed Nonhuman Primates

(2020) Blake J. Rust et al.   BLOOD

HIV-1 viremia not suppressible by antiretroviral therapy can originate from large T cell clones producing infectious virus

(2020) Elias K. Halvas et al.   JOURNAL OF CLINICAL INVESTIGATION

Recommendations for measuring HIV reservoir size in cure-directed clinical trials

(2020) Mohamed Abdel-Mohsen et al.   NATURE MEDICINE

Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer

(2020) Kathryn Lurain et al.   Current HIV/AIDS Reports

Multi-stakeholder consensus on a target product profile for an HIV cure

(2020) Sharon R Lewin et al.   Lancet HIV

The case for an HIV cure and how to get there

(2020) Mark Dybul et al.   Lancet HIV

Antigen-driven clonal selection shapes the persistence of HIV-1–infected CD4+ T cells in vivo

(2020) Francesco R. Simonetti et al.   JOURNAL OF CLINICAL INVESTIGATION

Single-cell characterization and quantification of translation-competent viral reservoirs in treated and untreated HIV infection

(2019) Marion Pardons et al.   PLoS Pathogens

PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals

(2019) Rémi Fromentin et al.   Nature Communications

HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation

(2019) Ravindra K. Gupta et al.   NATURE

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials

(2019) Yucai Wang et al.   JAMA Oncology

Anti-PD-1 Blockade with Nivolumab with and without Therapeutic Vaccination for Virally Suppressed Chronic Hepatitis B: A Pilot Study

(2019) Edward Gane et al.   JOURNAL OF HEPATOLOGY

Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study

(2019) Thomas S. Uldrick et al.   JAMA Oncology

Between a shock and a hard place: challenges and developments in HIV latency reversal

(2019) Jennifer M Zerbato et al.   Current Opinion in Virology

CXCR4-Using HIV Strains Predominate in Naive and Central Memory CD4+ T Cells in People Living with HIV on Antiretroviral Therapy: Implications for How Latency Is Established and Maintained

(2019) Michael Roche et al.   JOURNAL OF VIROLOGY

Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency

(2018) Vanessa A. Evans et al.   AIDS

Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection

(2018) E P Scully et al.   ANNALS OF ONCOLOGY

A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab

(2017) Petros Fessas et al.   SEMINARS IN ONCOLOGY

PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals

(2016) Riddhima Banga et al.   NATURE MEDICINE

Latency reversal and viral clearance to cure HIV-1

(2016) D. M. Margolis et al.   SCIENCE

CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART

(2016) Rémi Fromentin et al.   PLoS Pathogens

A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals

(2015) Francesco Andrea Procopio et al.   EBioMedicine

Programmed death-1 expression on CD4+ and CD8+ T cells in treated and untreated HIV disease

(2014) Leslie R. Cockerham et al.   AIDS

The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial

(2014) Ma Somsouk et al.   PLoS One

Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy

(2014) Julian H. Elliott et al.   PLoS Pathogens

A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection

(2013) David Gardiner et al.   PLoS One

Phosphorylation of CDK9 at Ser175 Enhances HIV Transcription and Is a Marker of Activated P-TEFb in CD4+ T Lymphocytes

(2013) Uri R. Mbonye et al.   PLoS Pathogens

DIVEIN: a web server to analyze phylogenies, sequence divergence, diversity, and informative sites

(2010) Wenjie Deng et al.   BIOTECHNIQUES

ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays

(2009) Yifang Hu et al.   JOURNAL OF IMMUNOLOGICAL METHODS

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

(2009) Nicolas Chomont et al.   NATURE MEDICINE